Bayer hopes to break into atherosclerosis setting with Xarelto filing

7 November 2017
xarelto_big

An application has been lodged with the European Medicines Agency to extend the label for Xarelto (rivaroxaban), in combination with aspirin, to treat coronary artery disease (CAD) or peripheral artery disease (PAD).

The submission for the Factor Xa inhibitor, sold by Germany’s Bayer (BAYN: DE), is supported by results of the Phase III COMPASS study, which was stopped at the start of the year based on the strength of the efficacy data.

Data from the study showed a 42% reduction in stroke and a 22% reduction in CV death, compared to aspirin alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical